CMS finalized a rule ending breakthrough-device shortcuts for Medicare add-on payments, with applications on or after Oct. 1, 2026 subject to standard rules.
Why it matters: The change makes it harder for device makers to secure early reimbursement support for costly products. Hospitals, manufacturers and investors could face a longer path to adoption and commercialization.
- CMS finalized the policy Aug. 3, 2026, according to STAT and CMS materials.
- The rule applies to inpatient new technology add-on payments, or NTAP, and outpatient device pass-through payments.
- Breakthrough devices will no longer bypass the usual substantial clinical improvement standard.
- CMS said applications received on or after Oct. 1, 2026 must use the standard eligibility rules.
CMS has ended a special Medicare payment route that let some FDA breakthrough devices qualify more easily for extra payments. The final rule removes the alternative pathway for both inpatient new technology add-on payments, or NTAP, and outpatient device pass-through payments. STAT reported the change.
Under the final policy, breakthrough devices will have to meet the usual requirement to show substantial clinical improvement to qualify for those add-on payments. CMS said in the final rule that it is standardizing the eligibility framework across technologies, and the rule was published in the Federal Register. CMS had previewed the rollback in the FY 2027 IPPS proposed rule, saying it wanted to repeal the special pathway.
The timing is split. CMS said applications received on or after Oct. 1, 2026 will be judged under the standard eligibility requirements. The payment-policy change itself takes effect in fiscal 2028, according to CMS materials and the final rule.
The policy matters because these payments can help hospitals adopt expensive new technologies while manufacturers build a reimbursement case. CMS created the inpatient alternative pathway in the FY 2020 IPPS rule and later extended a similar route in outpatient payment policy.
FDA and CMS are also building a separate Medicare coverage effort called RAPID, announced April 23, 2026, which FDA said can enable national Medicare coverage and payment as soon as two months after market authorization.
By the numbers
- Oct. 1, 2026 - date when new applications must follow the standard eligibility rules
- Fiscal 2028 - date when the payment policy change takes effect
- 1,284 - breakthrough designations FDA said it had granted as of March 31, 2026
Yes, but: CMS is changing the payment pathway, but the agency's separate Breakthrough Devices Program remains active.
What's next: CMS's fiscal 2028 payment-policy effective date is the next major milestone.